Correction: Thoratec attractive on any post-guidance weakness, says Oppenheimer Oppenheimer reports that Thoratec (THOR) will provide 2013 guidance on February 5, and the firm adds that the company has traditionally been conservative with its first outlook of the year. Oppenheimer thinks the stock may be muted in the near-term but it believes that the shares will have a number of positive catalysts later in the year. It recommends buying the shares on any pullbacks. A previous note incorrectly stated that this note from Oppenheimer was written about HeartWare (HTWR).
On The Fly: Analyst Upgrade Summary Today's noteworthy upgrades include: CyrusOne (CONE) upgraded to Buy from Hold at Stifel... MGIC Investment (MTG) upgraded to Conviction Buy from Buy at Goldman... NuVasive (NUVA) upgraded to Outperform from Market Perform at Wells Fargo... Phillips 66 (PSX) upgraded to Outperform from Neutral at Credit Suisse... Pinnacle Foods (PF) upgraded to Buy from Hold at Deutsche Bank... Rayonier (RYN) upgraded to Outperform from Sector Perform at RBC Capital.. Thoratec (THOR) upgraded to Outperform from Market Perform at Wells Fargo... Volcano (VOLC) upgraded to Outperform from Neutral at Credit Suisse... Progressive Waste (BIN) upgraded to Neutral from Underperform at Macquarie... Clean Harbors (CLH) upgraded to Outperform from Neutral at Wedbush... McGraw Hill Financial (MHFI) upgraded to Buy from Hold at Benchmark Co... Chesapeake (CHK) upgraded to Outperform from Market Perform at Bernstein... American Science & Engineering (ASEI) upgraded to Fair Value from Sell at CRT Capital... Sony (SNE) upgraded to Overweight from Equal Weight at Morgan Stanley.